.png){kind=small}
CoGenesis® AD
PriceFrom HK$6,000.00
阿茲海默症是最常見的認知障礙形式。根據世衛數據，阿茲海默症佔認知障礙個案的60-70%。
認知障礙症狀會在部份長者身上出現，但不是正常衰老的一部份。其中，有5%的病例屬於早發性阿茲海默症。了解阿茲海默症的基因變異有助評估早發或晚發性阿茲海默症的遺傳風險。
根據文獻，約35-60%的早發性阿茲海默症患者擁有家族病史。
Porter, T., Gozt, A.K., Mastaglia, F.L. and Laws, S.M. (2019). The Role of Genetics in Alzheimer's Disease and Parkinson's Disease. In Neurodegeneration and Alzheimer's Disease.
若擁有一組APOE4基因變異會比其他患者多2至3倍風險；若擁有兩組該基因變異發病的風險將會增加到10至15倍。
Van Cauwenberghe, C., Van Broeckhoven, C. & Sleegers, K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med 18, 421–430 (2016).
The testing options are as follows:
CoGenesis® Alzheimer's Disease (AD)
- The CoGenesis® AD test covers 6 high-risk genes associated with early-onset Alzheimer's disease. It is specifically designed for individuals already diagnosed with early-onset Alzheimer's disease, those who suspect they may have early-onset AD, or individuals with family members affected by early-onset AD.
CoGenesis® APOE
- The CoGenesis® APOE Genetic Test only covers the APOE gene, a high-risk gene associated with late-onset Alzheimer's disease. It is specifically designed for individuals already diagnosed with late-onset AD, those who suspect they may have late-onset AD, or individuals with family members affected by late-onset AD.
- If you wish to order the CoGenesis® APOE, please visit the product page provided.
No Reviews YetShare your thoughts.
Be the first to leave a review.
